

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis**

**This is a pre print version of the following article:**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1659222> since 2018-01-26T13:11:59Z

*Published version:*

DOI:10.1002/hep.29721

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

DRAFT

**What Are the Best Diagnostic Modalities for Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis and Associated Fibrosis? A Summary of AALSD Trend Conference in NASH (154/120)**

Zobair M. Younossi <sup>1</sup>, Rohit Loomba <sup>2</sup>, Mary E. Rinella <sup>3</sup>, Elisabetta Bugianesi <sup>4</sup>, Giulio Marchesini <sup>5</sup>, Brent A. Tetri<sup>6</sup>, Lawrence Serfaty <sup>7</sup>, Francesco Negro <sup>8</sup>, Stephen H. Caldwell <sup>9</sup>, Vlad Ratziu <sup>10</sup>, Kathleen E. Corey<sup>11</sup>, Scott L. Friedman <sup>12</sup>, Manal F. Abdelmalek <sup>13</sup>, Stephen A. Harrison <sup>14</sup> Arun J. Sanyal <sup>15</sup> Joel E. Lavine <sup>16</sup>, Philippe Mathurin <sup>17</sup>, Michael R. Charlton <sup>18</sup>, Zachary D. Goodman <sup>1</sup>, Naga P. Chalasani<sup>19</sup>, Quentin M. Anstee<sup>20</sup>, Kris V. Kowdley <sup>22</sup>, Jacob George<sup>23</sup> Keith Lindor<sup>24</sup>

1. Department of Medicine and Betty and Guy Beatty Center for Integrated Research, Claude Moore, Inova Health Systems, Falls Church, VA
2. University of California at San Diego, La Jolla, CA
3. Northwestern University Feinberg School of Medicine, Chicago, IL ,
4. University of Torino, Department of Medical Sciences, Torino, Italy
5. Università di Bologna, Bologna, Italy
6. Division of Gastroenterology and Hepatology, Saint Louis University, St. Louis, MO
7. Saint-Antoine Hospital, Paris, France
8. University Hospitals of Geneva, Geneva, Switzerland
9. Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA 22908
10. Institute of Cardiometabolism and Nutrition (ICAN) and Hospital Pitié Salpêtrière, de L'Hopital, Paris, France
11. Massachusetts General Hospital, Cambridge, MA
12. Icahn School of Medicine at Mount Sinai, Division of Liver Diseases, New York, NY
13. Division of Gastroenterology and Hepatology, Duke University, Durham, NC
14. Pinnacle Clinical Research, San Antonio, Texas 78233
15. Division of Gastroenterology, Virginia Commonwealth University, Richmond, VA
16. Department of Pediatrics, Columbia College of Physicians and Surgeons, New York, NY
17. Hôpital Claude Huriez Rue Michel Polonowski, Lille, France
18. Department of Medicine, University of Chicago. Chicago, IL
19. Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN
20. Institute of Cellular Medicine, Newcastle University, New Castle, UK
21. Swedish Medical Center, Seattle, WA
22. Jacob George
23. Arizona State University,

Running Title

Corresponding Author:

Zobair M. Younossi, MD, MPH

Betty and Guy Beatty Center for Integrated Research

Claude Moore Health Education and Research Building

3300 Gallows Road, Falls Church, VA 22042

Phone: (703) 776-2540 Fax: (703) 776-4386 Email: [zobair.younossi@inova.org](mailto:zobair.younossi@inova.org)

Words: 6290/6000

Tables

Figures

Conflict of Interest

Funding Source:

**Abbreviations:**

AFL: alcoholic fatty liver

NAFL- non-alcoholic fatty liver

NAFLD- non- alcoholic fatty liver disease

NASH- non-alcoholic steatohepatitis

AUROC- area under the curve

AASLD- American Association for the Study of Liver Diseases

ELF-enhanced liver fibrosis

HCC- hepatocellular carcinoma

PRO's- patient reported outcomes

NIH NASH CRN- National Institute of Health non-alcoholic steatohepatitis Clinical Research Network

**Abstract (284/275)**

Non-alcoholic fatty liver disease (NAFLD) represents a spectrum that ranges from isolated steatosis to non-alcoholic steatohepatitis (NASH), advanced fibrosis and cirrhosis. The majority of subject with NAFLD don't have underlying NASH without significant risk for adverse liver-related outcomes. The prevalence of NAFLD is about 24% with a gradient of high to low rates from Urban areas to rural of some of the Asian countries. Although relatively dynamic, patients with NASH are at risk for progressive liver disease and those with significant fibrosis are at the highest risk of mortality. Given the enormous prevalence of NAFLD, the clinical, economic and patient experience related burden of NAFLD and NASH can be enormous. The diagnosis of NASH is plagued with suboptimal modalities. Although liver biopsy is the most accurate modality to establish the diagnosis and stage of NASH, it suffers from being invasive and from observer variability in the pathologic interpretation of pathologic features of NASH. A number of approaches have been undertaken to non-invasively diagnose and establish the stage of NASH. These include predictive models such as NAFLD fibrosis score as well as "wet and dry biomarkers". Serum based biomarkers such ELF have been utilized to establish stage of fibrosis in NASH. Radiologic-based technologies such as transient elastography or MR elastography have been used to estimate significant fibrosis in NASH. Although quite dynamic field research, it seems that most modalities have AUROC between 0.76 to 0.90 %. In this context, MRE may have the best predictive performance for NASH. The issue of accurate diagnostic modalities in NAFLD is of utmost importance. Not only are these modalities important to risk stratify subjects for progressive liver disease but also to be used as endpoints of therapeutic clinical trials.

**Key words:** predictive models, noninvasive, biomarkers, imaging

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. Based on a recent meta-analysis, 25% of the general adult population in the world are potentially affected by NAFLD. [1] NAFLD seems to be more prevalent among males and Hispanics. [1]. Although very common in adults, the prevalence of NAFLD in children is also high and estimated to be around 10%. Similar to adults, NAFLD is most common in highest rates in Hispanic boys [2,3]. The data on the incidence of NAFLD are quite sparse. In fact, studies conducted in Israel and Asia have estimated NAFLD incidence to be between 28 to 52/1000 person-years, respectively [1]. These rates are probably higher, given the rising incidence of obesity and diabetes in adult population. Long long-term studies have suggested that most patients with NAFLD die primarily of cardiovascular complications [4-6]. Nevertheless, there is subgroup of subjects with NAFLD, primarily those with histologic NASH, and those with significant fibrosis who were at risk of developing advanced liver disease, hepatocellular carcinoma (HCC) and excess liver-mortality, and candidacy for liver transplantation (7-14). In addition to the clinical burden, NASH places significant burden on patient reported outcomes (PROs) and the economy [15-19]. A recent Decision Analytic Markov Model estimated tremendous economic burden of NAFLD and NASH to the US and European economies (20). These data provide strong evidence that the progressive form of NAFLD or NASH, especially those with significant fibrosis pose tremendous clinical, PRO and economic burden to the subjects and the society. In this context, two steps are important to deal with this important cause of liver disease. First, development of accurate, non-invasive, simple and inexpensive modalities to diagnose the potentially progressive form of NAFLD and enable clinicians to risk stratify these patients. Second, effective prevention strategies, or treatment regimens must be developed to manage the most progressive form of NAFLD. In this manuscripts, we will present the review of the literature and expert opinion about the state of diagnostic modality for NASH and fibrosis presented at a recent AASLD Trend Conference on NASH.

## ***Role of Histopathology in the Clinical Research and Management of Patients With NAFLD (Figures 1-4)***

The liver biopsy is the definitive technique for the diagnosis and classification of NAFLD in which the role of histopathology is to establish a diagnosis, characterize the lesions, and correlate the lesions with clinical outcome in the context of the natural history of the disease. (21-26) Historically, the terminology and concepts of the histopathologic features of NAFLD were derived from alcoholic liver disease. Thus, alcoholic fatty liver (AFL) is analogous to simple steatosis (NAFL), alcoholic hepatitis to nonalcoholic steatohepatitis (NASH), and alcoholic cirrhosis to the cirrhotic stage of NAFLD. Although there may be differences in degree, the features are sufficiently similar to preclude an etiologic diagnosis based on histology alone. Therefore, the characteristic histopathologic features which are investigated when diagnosing AFL or NAFL include: 1). Fat – hepatocellular triglyceride accumulation, 2). Hepatocellular injury in the centrilobular location which is most severe in the acinar zone, 3). Cytoskeletal damage shown as hepatocellular ballooning with or without Mallory-Denk bodies, 4). Parenchymal inflammation where lymphocytes and macrophages predominate, though neutrophils may be present in severe cases, and 5). Perisinusoidal fibrosis seen as collagen deposition in the space of Disse. **(Figure 1)**

As an aid to help characterize these lesions and allow for statistical analysis in clinical trials, the pathologists of the National Institute of Health NASH Committee (NIH NASH CRN) devised a grading system called the NAFLD Activity Score (NAS). (27) **(Figures 2 and 3)** After studying the inter- and intra-observer variability of a variety of histologic features, the features with the greatest reproducibility (severity of steatosis, hepatocellular ballooning, and lobular inflammation) were chosen to formulate the NAS score. The NAS system then assigns a numerical grade to each feature such that the severity of steatosis is graded from zero to three (0 to 3), hepatocellular ballooning is graded from zero to two (0 to 2), and lobular inflammation is

graded from zero to three (0 to 3). The NAS score is the unweighted sum of these three numbers with a range from zero to eight (0 to 8). Improvement in histologic severity is accompanied by a decrease in the NAS. (27)

However, the histologic feature with the greatest reproducibility was found to be fibrosis, a feature which is not part of the NAS score because fibrosis is considered a sign of the stage of disease rather than a grade of injury. Fibrosis staging is, therefore, scored separately.

Accordingly, the NASH CRN system is used to grade fibrosis where stage 0 = no fibrosis; stage 1 = centrilobular pericellular fibrosis; stage 2 = centrilobular and periportal fibrosis; stage 3 = bridging fibrosis; and stage 4 = cirrhosis. (5,11) (**Figure 4**)

As a result of this histologic work done on NAFLD, the natural history of the various lesions associated with NAFLD are gradually being elucidated. For example, fatty liver, alone or with some lobular inflammation but without evidence of cytoskeletal damage (ballooning or Mallory-Denk bodies) or fibrosis, has long been considered a benign, non-progressive disease; however, recent follow-up studies, have found that some patients do, in fact, eventually develop fibrosis and even cirrhosis. (28) Another example, NASH with ballooning  $\pm$  Mallory-Denk bodies, was long thought to be the progressive form of NAFLD; however, recent long-term follow-up studies have found that the single histologic feature that predicted mortality was not NASH but fibrosis in the liver biopsy. (5,11,28) Furthermore, studies of NAFLD patients with paired biopsies found that spontaneous regression of fibrosis may be as common as fibrosis progression, both in the long-term and short-term.

Liver biopsies are considered the gold standard for diagnosing NAFLD and its progression. Through a collaborative effort with NIH NASH CRN, two scoring systems were developed to grade the level of liver injury associated with NAFLD (NAS) and stage the level of disease associated with NAFLD- fibrosis score. As such, the use of histology in diagnosing NAFLD has

allowed a more in-depth understanding of the natural history of the various NAFLD histologic lesions, but more information is still needed on the mechanisms of fibrosis progression and development of cirrhosis in patients with NAFLD.

### ***The Role Radiologic Modalities for Diagnosing, Staging and Monitoring NASH ( figure 5-8)***

Though, liver biopsy is the gold standard to diagnose NASH and assess the stage of fibrosis in patients with NAFLD, it has many limitations including cost, sampling error, complications leading to morbidity, and though rare, death. [29] However, when a clinician sees a patient for the first time with suspected NAFLD he/she would like to know the following: 1) Whether the patient has NAFLD, 2) Whether the patient is likely to have underlying NASH, 3) Whether the patient has any fibrosis, 4) Whether the patient has any advanced fibrosis? As a result there is an urgent need for an accurate non-invasive diagnostic modalities for the diagnosis and staging of NAFLD and NASH. [30]

In the context of NAFLD, the first challenge is to accurately show presence of fat in the liver which 33% of fat is thought to be the optimal level for detecting hepatic steatosis (11,29-34). In fact, fat is thought to have its own chemical signature which can be detected directly by magnetic resonance spectroscopy (MRS). When performed properly, MRS quantifies the proton density fat fraction (PDFF), a standardized measure of liver tissue [TG]. However, the limitations of MRS include: restricted coverage, need for expertise in protocol prescription, data collection and spectral analysis is required, while MRS is not available on routine scanners. (11-32-35). Like conventional in-phase and opposed-phase, MRI- Proton Density Fat Fraction (PDFF), addresses confounding factors and is not affected by scanner field strength, patient factors ( age, sex, BMI, etiology of liver disease) and concomitant liver abnormalities such as iron overload or necroinflammation. (11,32-35) (**Figure 8**)



In contrast, fibrosis has no molecular signature that can be detected by current imaging techniques so all imaging tests for fibrosis attempt to detect fibrosis indirectly using proposed biomarkers which include: stiffness, diffusion, perfusion, metabolites, and image texture. However, the leading biomarker is liver “stiffness” (or “elasticity”) and its family of related parameters. The rationale for using “stiffness” or “elasticity” is that the collagen deposition associated with fibrosis imparts parenchymal rigidity which on imaging tests is considered assessing “stiffness” or “elastography”. (36-40)

The most accurate noninvasive methods which assess the stiffness of the liver and dichotomizes the patient into advanced versus non-advanced fibrosis include Fibroscan, Magnetic Resonance Elastography (MRE) and emerging techniques such as Shear Wave Elastography and Acoustic Radiation Force Imaging. [35-43] **(Figures 5,6,7)**

MRE sensitivity has been shown when using a “stiffness” cutoff of 3.63 kPa had a sensitivity of 0.86 (95% confidence interval [CI]: 0.65-0.97), a specificity of 0.91 (95% CI: 0.83-0.96), a positive predictive value of 0.68 (95% CI: 0.48-0.84), and a negative predictive value of 0.97 (95% CI: 0.91-0.99) with an area under the curve (AUC) of advanced of 0.924 for diagnosing advanced fibrosis. (Figure) (44) In addition, the use of 3D MRE has shown that at 40Hz and a “stiffness” cutoff of 2.43 an AUC of 0.962 for diagnosing advanced fibrosis. (17) In fact, in a recent study comparing ultrasound based versus MRE-based NAFLD fibrosis assessment, MRE was significantly better (43) (Figure) Further, MRE was significantly better than TE when diagnosing advanced fibrosis.[43]

Though transient elastography or other ultrasound-based tests are more accessible and easier to use, they are limited when used in patients with obesity, ascites, acute inflammation, or cirrhosis. However, even though, the 3D MRE is able to overcome all these issues except for iron overload or acute inflammation, it is limited by the having restricted accessibility at many

centers and the required expertise needed to obtain adequate tests. So, as of now, accurate imaging is a trade off between specificity, accessibility, and ease of use such that as specificity goes up accessibility and ease go down. Further research is needed to quantify the exact trade off that occurs when one imaging technique is traded off for the other.

### ***Noninvasive Biomarkers in NASH***

In addition to the non-invasive tests based on the imaging modalities, there is an attempt to define non-invasive biomarkers using predictive models or serum biomarkers. These non-invasive markers include those that are based on alanine aminotransferase levels, those that include components of metabolic syndrome, measuring circulating keratin18 fragment levels as well as tests based on soluble markers such as Fibrometer, microRNA panels, and lipidomic panels. [30,31,42-45]

Using these non-invasive tests to diagnose for NASH current studies have found that the frequency of NASH in individuals with normal ALT (<35 U/L) was 11% whereas the frequency was 29% in those with elevated ALT ( $\geq 35$  U/L) and if the ALT was two times the upper limit of normal (>70 U/L), predicting NASH was found to have a 50% sensitivity and 61% specificity for NASH. Another study found that individuals with NAFLD can have normal ALT levels as the disease progresses (30)

Feldstein et al., in their seminal work, found that circulating levels of keratin-18 fragments were predictors of NASH in patients with NAFLD.[46] Since the release of their observations, there has been intense investigations which have unequivocally found that increased circulating levels of keratin 18 fragments are associated with NASH. However, at the same time, there are a number of issues with this diagnostic method (lack of a commercially available clinical test, the ability for the results to be reproducible and a lack of a clear cut-off point) which limit its clinical utility at the present time.

Other have looked into combining these different measures to diagnose NASH. The NASH Test, combines demographic characteristics (age, gender, and BMI) with serum parameters (aminotransferases and lipids), and with alpha-2 macroglobulin, ApoA1, and haptoglobin. The NASH Test sensitivity is 33 %, and its specificity is 94% indicating it has a good negative predictive value (NPV) for NASH (81%) [47]. Another combined test, The NASH Diagnostics Panel, which uses the presence of CK-18 fragments, adiponectin, and resistin initially performed well but in a larger study was not found to be as effective. [48]. The NAFLD Diagnostic Panel, used CK-18 fragments in combination with the presence of type II diabetes mellitus, triglycerides, and gender, but it did not perform any better than the NASH Diagnostics Panel [49]. Several prognostic scores (Palekar score, Shimada index, Nice model, Gholam's model), have also been developed with all performed somewhat similarly with AUROC ranging from 0.76 to 0.90 [50-52].

Metabolic syndrome is another commonly used index to identify individuals with NAFLD at risk for NASH. Several studies have found a significant relationship between the increasing number of metabolic syndrome components and the likelihood of NASH in patients with NASH.(13) Yet, what has not been explored is the combination of metabolic syndrome, levels of ALT and age to predict NASH in NAFLD leaving another area of further exploration.

With these continuing challenges in correctly diagnosing NASH, the NAFLD scientific community needs to reevaluate the need for predicting NASH in patients with NAFLD. Should we instead focus on NASH with stage  $\geq 2$  fibrosis as it is the sub-phenotype that is primarily targeted in Phase 2B and Phase 3 clinical trials?

### ***Serum Fibrosis Markers in Non-alcoholic Steatohepatitis (9-14)***

Since stage of fibrosis is the most important predictor of outcome, a great deal of effort has focused on determining presence of fibrosis. In this context, NAFLD biomarkers have been

codified within three FDA BEST biomarker target domains: 1) Diagnostic Markers reflect current stage of fibrosis; 2) Prognostic Markers stratify individuals by fibrosis progression risk, discriminating fast vs. slow progressors and/or predicting long-term outcomes and hard endpoints; and 3) Monitoring Markers used to track disease progression or treatment response. Such biomarkers may be at one of four qualification levels: 1) Exploration (early-phase experimental biomarkers), 2) Demonstration (“probable valid” biomarkers), 3) Characterisation (“known valid” biomarkers), and 4) Surrogacy (registerable “surrogate endpoint”). **(Figure 9)** Although there has been some progress in biomarker development for detection of advanced fibrosis, existing biomarkers are generally at the first two qualification levels and need validation. Therefore, serological markers for the evaluation of liver fibrosis are divided into ‘indirect’ markers (that reflect alterations in hepatic function but not collagen turnover, e.g. platelet levels) and ‘direct’ markers [associated with extracellular matrix (ECM)] deposition and turnover).

[53,54]

### **Indirect Markers and ‘Simple Panels’**

Significant hepatic fibrosis can lead to hepatocellular dysfunction and portal hypertension, which are reflected by changes in standard biochemical and haematological parameters. These tests, alone or combined as ‘simple panels’, are potentially attractive clinical tools as they are inexpensive and many indices are already routinely measured in patients with liver disease. [54]

The results of a head-to-head comparison in a large cohort with biopsy-proven NAFLD patients have been published 4. In general, simple panels have relatively robust NPV and so can reliably exclude advanced fibrosis but have poor positive predictive value (PPV) (ranging from 27-79%).

[55] Although, these tests are unreliable at diagnosing advanced fibrosis they do have the potential to help with the triage of patients by reliably excluding advanced fibrosis. Using such tests may help to mitigate the healthcare burden such a large ‘at risk’ population places on

resources by not allowing those considered 'low-risk' scores to not have to undergo further investigation. (**Figure 11**)

In some case, advancing fibrosis serum ALT falls whereas AST remains stable or increases. The consequent increase in the AST/ALT ratio is a component of many of the simple panels. The NAFLD Fibrosis Score (NFS) is calculated using six routinely measured parameters found to be independently associated with advanced fibrosis on multivariate analysis. By applying a low cut-off ( $<1.455$ ), advanced fibrosis can be excluded with high accuracy (NPV 93%) whilst a high cut-off threshold ( $>0.676$ ) offers accurate detection of advanced fibrosis (PPV 90%). [56] Use of this score has been suggested to reduce the need for liver biopsy by ~75%. This score has been independently validated and although the formula appears daunting, calculation can be performed using a simple online calculator ([www.nafldscore.com](http://www.nafldscore.com)).

The FIB4 Score is one of the best performing simple non-invasive tests for advanced fibrosis in NAFLD. A score of  $<1.3$  has a 90% NPV for stage 3-4 fibrosis, whilst a score of  $>2.67$  had an 80% PPV with only a quarter of the cohort being unclassified 1.3 or above 2.67. [57] Other studies have also found that the FIB-4 score narrowly out performs other simple non-invasive tests in predicting advanced fibrosis. [55] The specificity for advanced fibrosis using the FIB-4 and NFS declines with age, becoming unacceptably low however age-adjusted lower cut-offs (NFS  $<0.12$  and FIB4  $<2$ ) have been derived to exclude advanced fibrosis in those aged  $\geq 65$ -years. [58]

### **Direct Markers: Collagen Turnover**

As a result of repeated injury to the liver, liver regeneration eventually fails and hepatocytes are replaced by an ECM composed of collagens (I, III, and IV), fibronectin, undulin, elastin, laminin, hyaluronan, and proteoglycans 3. Candidate biomarkers deriving from these processes are appealing targets and so this is an area of active research.[59,60] (**Figure 12**)

One such biomarker is Hyaluronic acid (HA). HA production is increased when collagen synthesis is accelerated so is a marker of the increased ECM production. Similarly, liver fibrosis results in the deposition of collagen and release of pro-peptides, predominantly Pro-Collagen III (PIIINP). The terminal peptide of PIIINP correlates with the NAFLD activity score (NAS), and its constituent components ( $P < 0.001$ ). A threshold of 6.6 ng/mL gave a NPV for advanced fibrosis of 95%-97% and 100% for cirrhosis. [59]. The Enhanced Liver Fibrosis (ELF®) test is a commercial panel of markers focusing on matrix turnover that comprises tissue inhibitor of matrix metalloproteinase 1 (TIMP 1), hyaluronic acid (HA), and aminoterminal peptide of pro-collagen III (P3NP). [61] When compared with the NAFLD fibrosis score this test performed only marginally better for severe fibrosis (AUROC 0.93 vs 0.89) and moderate fibrosis (AUROC 0.90 vs 0.86), but combining the two enhanced efficacy (AUROC 0.98 for severe fibrosis and 0.93 for moderate fibrosis). [62] Fibrotest® 11 is another commercial panel, with a reported AUROC of 0.75-0.86 for F2-F4 and 0.81-0.92 for F3-F4. Other commercial assays in development detect pathologically modified proteins generated by specific proteases. Specific collagen fragments such as Pro-C3 and Pro-C6 may be detected using proprietary Protein Fingerprint™ ELISA assays and have thus far provided promising results. [63]

### **Other Promising Experimental Markers (Genetics/Epigenetics, Metabolomics, Lipidomics)**

Inter-patient variation in NAFLD progression risk is, at least in part, determined by genetic modifiers that influence individual response to environmental (diet, lifestyle) factors. Mounting evidence indicates that epigenetic factors such as differential DNA methylation and circulating cell-free DNA methylation signatures in plasma, may potentially stratify patients with NAFLD into mild versus severe fibrosis. [64,65] **(Figure 13)** MicroRNA (miRNA) is another genetic marker that appears to be relatively stable and can be detected in plasma following release from injured tissue and may serve as another disease biomarker. [66,67] **(Figure 14)**

Dysregulation of liver lipid metabolism is central to the development of NAFLD and may also offer the potential for development of novel biomarkers. This is exemplified by a metabolomics/lipidomic approaches that can distinguish between NAFL and NASH [17]. Other plasma-based lipidomic biomarkers that identify and potentially stage hepatic fibrosis have been developed with algorithms to discriminate between F0 vs. F1-4 (AUROC  $0.92\pm 0.02$ ) and between early vs. advanced fibrosis (AUROC  $0.89\pm 0.03$ ). [68] These, like the majority of the direct markers discussed above, require further validation before they are likely to be widely used in routine clinical practice.

### **Summary:**

Over the last forty years, NAFLD has evolved from an unrecognized entity or to a heterogeneous collection of overlapping liver disease with a common phenotype of having hepatic steatosis. Although NAFLD is quite common, nearly affecting about 25% of the world's adult population, it is increasingly clear that subjects with NASH and especially those with significant fibrosis are at greatest risks for excess mortality and adverse clinical outcomes as well as impairment of PRO and significant economic burden.

However, despite the growing recognition of this important burden, there are significant challenges to accurately and non-invasively diagnose the progressive form of NAFLD. Although liver biopsy is considered the current imperfect "gold" standard for diagnosing NASH and staging fibrosis, it is an invasive procedure with some variability in assessment of key feature of NASH. In fact, in 2017, the regulatory bodies requires histologic endpoints for approval of drugs and diagnostic modalities. Nevertheless, a number of serum markers, radiographic modalities, and noninvasive predictive algorithms have been investigated. Most of these modalities suffer from suboptimal performance. In this context, MRI-PDFF seems to be the most accurate modality for detecting hepatic fat. In contrast, MRE seems to be the most accurate test for

staging liver disease. The combination of MRI-PDFF and MRE can provide a relatively accurate method to risk stratify subjects with NAFLD. On the other hand, availability of these modalities present a major challenge to most clinical practices.



## References

1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016,64:73–84
2. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. *Pediatrics*. 2006 Oct;118(4):1388-93
3. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. *Clin Liver Dis*. 2009 Nov;13(4):511-31. doi: 10.1016/j.cld.2009.07.005
4. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? *Atherosclerosis* 2013,230:258-67.
5. Mellinger JL, Pencina KM, Massaro JM, Hoffmann U, Seshadri S, Fox CS, et al. Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham Heart Study. *J Hepatol* 2015,63:470-6.
6. Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, et al. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. *World J Gastroenterol* 2016,22:9674-9693.
5. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatchoenwittaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology* 2015,149:389-97.e10.
6. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. *Hepatology* 2013,57:1357-65.
7. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. *Hepatology*. 2017 May;65(5):1557-1565. doi: 10.1002/hep.29085. Epub 2017 Mar 31
8. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. *Gastroenterology*. 1999 Jun;116(6):1413-9
9. Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: a practical approach to evaluation and management. *Clin Liver Dis*. 2009 May;13(2):249-66. doi: 10.1016/j.cld.2009.02.009
10. Anstee QM, Seth D, Day CP. Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease. *Gastroenterology*. 2016 Jun;150(8):1728-1744.e7. doi: 10.1053/j.gastro.2016.01.037. Epub 2016 Feb 10.

11. Younossi ZM, Stepanova M, Rafiq N, Makhoul H, Younoszai Z, Agrawal R, Goodman Z. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. *Hepatology*. 2011 Jun;53(6):1874-82. doi: 10.1002/hep.24268. Epub 2011 May 14
12. Younossi ZM, Stepanova M, Rafiq N, Henry L, Loomba R, Makhoul H, Goodman Z. Nonalcoholic Steatofibrosis Independently Predicts Mortality in Nonalcoholic Fatty Liver Disease. *Hepatology Communications*. In press.
13. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. *Gastroenterology*. 2015 Mar;148(3):547-55. doi: 10.1053/j.gastro.2014.11.039. Epub 2014 Nov 25
14. Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC, Charlton M. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. *Gastroenterology*. 2017 Apr;152(5):1090-1099.e1. doi: 10.1053/j.gastro.2017.01.003. Epub 2017 Jan 11
15. Sayiner M, Stepanova M, Pham H, Noor B, Walters M, Younossi ZM. Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. *BMJ Open Gastroenterol*. 2016 Aug 16;3(1):e000106. doi: 10.1136/bmjgast-2016-000106. eCollection 2016
16. Younossi ZM, Stepanova M, Henry L, Racila A, Lam B, Pham HT, Hunt S. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. *Liver Int*. 2017 Feb 17. doi: 10.1111/liv.13391. [Epub ahead of print]
17. Sayiner M, Otgonsuren M, Cable R, Younossi I, Afendy M, Golabi P, Henry L, Younossi ZM. Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis. *J Clin Gastroenterol*. 2017 Mar;51(3):254-260.
18. Younossi ZM, Zheng L, Stepanova M, Henry L, Venkatesan C, Mishra A. Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease. *J Clin Gastroenterol*. 2015 Mar;49(3):222-7.
19. Younossi, Z. What Is the Ethical Responsibility of a Provider When Prescribing the New Direct-Acting Antiviral Agents to Patients With Hepatitis C Infection? *Clinical Liver Disease* 2015. 6 (5): 117-119.
20. Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, Racila A, Hunt S, Beckerman R. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. *Hepatology*. 2016 Nov;64(5):1577-1586. doi: 10.1002/hep.28785. Epub 2016 Sep 26.

21. Ludwig J, Viggiano TR, McGill DB, Ott BJ: Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc* 1980; 55:434-438.
22. Schaffner F, Thaler H: Nonalcoholic fatty liver disease. *Prog Liver Dis* 1986; 8:283-298.
23. Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J, Rybicki L: Nonalcoholic fatty liver disease; Assessment of variability in pathologic interpretations. *Mod Pathol* 1998; 11:560-565.
24. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ: Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity.
25. Stumptner C, Fuchsbichler A, Heid H, Zatloukal K, Denk H: Mallory body – A disease-associated type of sequestrosome. *Hepatology* 2002; 35:1053-1062.
26. Telli MR, James OFW, Burt AD, Bennett MK, Day CP: The natural history of nonalcoholic fatty liver. *Hepatology* 1995; 22:1714-1719.
27. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005; 41:1313-1321.
28. Kleiner DE, Makhlouf HR: Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children. *Clin Liver Dis* 2016; 20:293-312.
29. Jayakumar J, Harrison SA, Loomba R. Noninvasive markers of fibrosis and inflammation in nonalcoholic steatohepatitis. *Curr Hepatol Rep* 2016; 15:86-95.
30. Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). *Liver International* 2013; 33:1398-1405
31. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. *Hepatol* 2003;37:917–923.
32. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology* 2012;55:2005-23.
33. Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. *Nat Rev Gastroenterol Hepatol* 2013;10:666-75.
34. Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. *J Hepatol* 2016;65:1006-1016.

35. Tapper EB, Challies T, Nasser I, et al. The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease. *The American journal of gastroenterology* 2016.
36. Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. *Gastroenterology* 2016.
37. Chen J, Yin M, Talwalkar JA, et al. Diagnostic Performance of MR Elastography and Vibration-controlled Transient Elastography in the Detection of Hepatic Fibrosis in Patients with Severe to Morbid Obesity. *Radiology* 2016:160685.
38. Hu, Houchun H., Krishna S. Nayak, and Michael I. Goran. "Assessment of Abdominal Adipose Tissue and Organ Fat Content by Magnetic Resonance Imaging." *Obesity reviews : an official journal of the International Association for the Study of Obesity* 12.501 (2011): e504–e515. PMC. Web. 5 Apr. 2017.
39. Thomsen H, Kaatsch HJ, Asmus R. Magnetic resonance imaging of the brain during alcohol absorption and elimination--a study of the "rising tide phenomenon." *Blutalkohol*. 1994 May;31(3):178-85
40. Hamilton G, Middleton MS, Bydder M, Yokoo T, Schwimmer JB, Kono Y, Patton HM, Lavine JE, Sirlin CB. Effect of PRESS and STEAM sequences on magnetic resonance spectroscopic liver fat quantification. *J Magn Reson Imaging*. 2009 Jul;30(1):145-52. doi: 10.1002/jmri.21809
41. Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy. *J Magn Reson Imaging*. 2011 Oct;34(4):spcone
42. Hu C, Wei H, van den Hoek AM, Wang M, van der Heijden R, Spijksma G, Reijmers TH, Bouwman J, Wopereis S, Havekes LM, Verheij E, Hankemeier T, Xu G, van der Greef J. Plasma and liver lipidomics response to an intervention of rimonabant in ApoE\*3Leiden.CETP transgenic mice. *PLoS One*. 2011;6(5):e19423. doi: 10.1371/journal.pone.0019423. Epub 2011 May 17
43. Cusi K, Chang Z, Harrison S, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. *J Hepatol* 2014;60:167–174
44. Rinella ME, Loomba R, Caldwell SH, Kowdley K, Charlton M, Tetri B, Harrison SA. Controversies in the Diagnosis and Management of NAFLD and NASH. *Gastroenterol Hepatol (N Y)*. 2014 Apr;10(4):219-27
45. Jayakumar J, Harrison SA, Loomba R. Noninvasive markers of fibrosis and inflammation in nonalcoholic steatohepatitis. *Curr Hepatol Rep* 2016; 15:86-95.

46. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. *Hepatology*. 2009 Oct;50(4):1072-8. doi: 10.1002/hep.23050
47. Anty R, Iannelli A, Patouraux S, et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. *Aliment Pharmacol Ther*. 2010;32(11-12): 1315–22.
48. Yilmaz Y, Ulukaya E, Dolar E. A Biomarker biopsy for the diagnosis of NASH: promises from CK-18 fragments. *Obes Surg*. 2008;18(11):1507–8.
49. Younossi ZM, Page S, Rafiq N, et al. A biomarker panel for nonalcoholic steatohepatitis (NASH) and NASH-related fibrosis. *Obes Surg*. 2011;21(4):431–9.
50. Palekar NA, Naus R, Larson SP, et al. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. *Liver Int*. 2006;26(2):151–6.
51. Shimada M, Kawahara H, Ozaki K, et al. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. *Am J Gastroenterol*. 2007;102(9):1931–8.
- 52. Younossi 2017**
53. Pinzani M, Vizzutti F, Arena U, et al. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. *Nat Clin Pract Gastroenterol Hepatol* 2008;5:95-106.
54. Dyson JK, McPherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. *J Clin Pathol* 2013;66:1033-45.
55. McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. *Gut* 2010;59:1265-9.
56. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology* 2007;45:846-54.
57. Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2009;7:1104-12.
58. McPherson S, Hardy T, Dufour JF, et al. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. *Am J Gastroenterol* 2016.
59. Tanwar S, Trembling PM, Guha IN, et al. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. *Hepatology* 2013;57:103-11.

60. Karsdal MA, Henriksen K, Nielsen MJ, et al. Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. *Am J Physiol Gastrointest Liver Physiol* 2016;311:G1009-G1017.
61. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. *Gastroenterology* 2004;127:1704-13.
62. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. *Hepatology* 2008;47:455-60.
63. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. *BMC Gastroenterol* 2006;6:6.
64. Zeybel M, Hardy T, Wong YK, et al. Multigenerational epigenetic adaptation of the hepatic wound-healing response. *Nature Medicine* 2012;18:1369-77.
65. Hardy T, Zeybel M, Day CP, et al. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. *Gut* 2016.
66. Pirola CJ, Fernandez Gianotti T, Castano GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. *Gut* 2015;64:800-12.
67. Tan Y, Ge G, Pan T, et al. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. *PLoS One* 2014;9:e105192.
68. Barr J, Caballeria J, Martinez-Arranz I, et al. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. *J Proteome Res* 2012;11:2521-32.